Shares of Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 1,180,780 shares traded hands during mid-day trading, an increase of 98% from the previous session’s volume of 596,942 shares.The stock last traded at $6.6050 and had previously closed at $6.86.
Wall Street Analyst Weigh In
Separately, Sanford C. Bernstein raised shares of Coloplast A/S to a “hold” rating in a research note on Wednesday, January 28th. Three analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.
Get Our Latest Stock Report on Coloplast A/S
Coloplast A/S Stock Down 4.4%
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last posted its quarterly earnings results on Friday, February 6th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.09 by $0.01. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.12 billion. Coloplast A/S had a net margin of 14.35% and a return on equity of 27.87%. As a group, analysts predict that Coloplast A/S Sponsored ADR will post 0.31 earnings per share for the current fiscal year.
About Coloplast A/S
Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.
In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.
Further Reading
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
